Psych Congress Network

We're live! Our debate on muscarinic agonists in schizophrenia treatment is underway. If you haven't joined yet, it's not too late—tune in now to hear insights from Dr. Andrew J. Cutler and Dr. Greg Mattingly. Join the conversation: https://hubs.ly/Q039sNz_0

Last chance to join our live debate today on muscarinic agonists in schizophrenia treatment! This is your final opportunity to hear from experts Dr. Andrew J. Cutler and Dr. Greg Mattingly. Register now and be part of the conversation—today, from 12:00 PM to 1:00 PM ET. https://hubs.ly/Q038_SBq0

Tomorrow is the day! Join us for a live debate on muscarinic agonists in schizophrenia treatment with experts Dr. Andrew J. Cutler and Dr. Greg Mattingly. Don't miss this accredited, complimentary session—register today and join us tomorrow, February 5, from 12:00 PM to 1:00 PM ET. https://hubs.ly/Q039bbhn0

Join us this week for a live discussion on muscarinic agonists in schizophrenia treatment. Mark your calendar for Wednesday, February 5 from 12:00 PM to 1:00 PM ET. Secure your complimentary, accredited spot and gain fresh insights from top experts like Dr. Andrew J. Cutler and Dr. Greg Mattingly. Register here: https://hubs.ly/Q038Sjnz0 #Schizophrenia #MedicalDebate #Webinar #CME

In just ONE WEEK, Dr. Andrew J. Cutler and Dr. Greg Mattingly will go head-to-head in our latest webinar, Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment. Join this lively accredited debate on Wednesday, March 5, to learn how muscarinic agonists could shape the future of schizophrenia care. Explore new perspectives on patient outcomes and get your questions answered with live Q&A! Register now: https://hubs.ly/Q038jbBl0 #Schizophrenia #MedicalDebate #CME #MentalHealth

Struggling with monotherapy vs. adjunctive use of muscarinic agonists in schizophrenia treatment? Join our complimentary webinar, Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment, on Wednesday, March 5, where we'll tackle this very question! Learn from leading experts Dr. Cutler and Dr. Mattingly as they debate the latest evidence and best practices. https://hubs.ly/Q037RlJw0

Join our virtual session exploring strategies for managing adverse effects of adjunct atypical antipsychotics in inadequately treated major depressive disorder (MDD). Gain insights into the challenges of treating MDD with standard antidepressants, such as nonresponse, persistent symptoms, and difficulty achieving remission. Complete the session to earn CME/CE credits: https://hubs.ly/Q035BJ-x0 #depression #DepressionCare #psychcme #CME #CMEcredits #cmeeducation #continuingeducationcredits

Join us for an on-demand session describing the significance of anhedonia in major depressive disorder (MDD), as well as challenges associated with its recognition and resistance to standard interventions. After streaming the session, you'll have the opportunity to claim complimentary CME/CE credits! Stream now: https://hubs.ly/Q035BHRj0 #MDD #depressiontreatment #depressionawareness #psychcme #CME #CMEcredits #cmeeducation #continuingeducationcredits "

With muscarinic agonists emerging as a potential new option in schizophrenia treatment, the big question is: should they be used as first-line therapy, or are they better suited for later stages? Join top experts in a debate-style webinar as they tackle this crucial topic, weighing the risks, benefits, and clinical evidence behind early adoption vs. a cautious approach. Claim your complimentary registration for our upcoming accredited webinar, Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment, and join us on Wednesday, March 5, from 12:00-1:00 PM. https://hubs.ly/Q0375XlH0

The schizophrenia treatment landscape is evolving, but where do muscarinic agonists fit alongside anticholinergic agents? Join leading experts on Wednesday, March 5, for a debate-style webinar as they tackle this critical question, exploring the mechanistic differences, clinical implications, and what it all means for patient care. Learn more and claim your complimentary registration: https://hubs.ly/Q0375WbL0